REFERENCES
- Department of Health and Human Services (DHHS) Panel on Clinical Practices for Treatment of HIV Infection. Guide-lines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. Panel report March 23, 2004. Available at: http://www.aidsinfo.nih.gov/Guidelines/
- The EACS Euroguidelines Group. European guidelines for the clinical management and treatment of HIV-infected adults in Europe. 2005. Available at: www.eacs.eu. Accessed December 27, 2005.
- Eron J Jr, Yeni P, Gathe J Jr, et al; KLEAN study team. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a ran-domised non-inferiority trial. Lancet. 2006;368:476–482.
- Panel on Antiretroviral Guidelines for Adults and Adoles-cents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008; 1–128. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed June 26, 2008.
- Clumeck N, Pozniak A, Raffi F; EACS Executive Commit-tee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med. 2008;9:65–71.
- Murphy RL, da Silva BA, Hicks CB, et al. Seven-year effi-cacy of a lopinavir/ritonavir-based regimen in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials. 2008;9:1–10
- Hicks C, King MS, Gulick RM, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS. 2004;18:775–779.
- Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med. 2007;15:119–125.
- Division of AIDS, NIAID. Division of AIDS Table for GradingSeverity of Adult Adverse Experiences. Rockville, MD: National Institute of Allergy and Infectious Diseases; 1992.
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive Summary. Washington, DC: National Heart, Lung, and Blood Institute, National Institutes of Health; May 2001. NIH Publication No. 01–3670.
- King MS, Bernstein BM, Walmsley SL, et al. Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir-ritonavir, in antiretroviral therapy-naive patients. J Infect Dis. 2004;190:280–284.
- Murphy R, Da Silva BA, Hicks CB, et al. Seven-year efficacy of a lopinavir/ritonavir based regimen in antiretroviral-naive HIV-1 infected patients. HIV Clin Trials. 2008;9:1–10.
- Smith KY, Fine D, Patel P, et al. Similarity in efficacy and safety of abacavir/lamivudine (ABC/3TC) compared to tenofovir/emtricitabine (TDF/FTC) in combination with QD Lopinavir/Ritonavir (LPV/r) over 96 weeks in the HEAT Study. Presented at: 17th International AIDS Conference; August 3–8, 2008; Mexico City, Mexico.
- Lundgren J, Reiss P, Worm S, et al and Aquataine, AHOD, ATHENA, INSIGHT, EuroSIDA, ICONA, Nice, SHCS, St Pierre Cohorts and D:A:D Study Group. Risk of myo-cardial infarction with exposure to specific ARV from PI, NNRTI and NRTI drug classes. In: Programs and abstracts for the 16th Conference on Retroviruses and Opportunis-tic Infections; February 8–11, 2009; Montreal, Canada. Abstract 44LB
- Lang S, Mary-Krause M, Cotte L, et al and the Clini-cal Epi Group of the French Hospital Database on HIV. Impact of specific NRTI and PI exposure on the risk of myocardial infarction: a case-control study nested within FHDH ANRS C04. In: Programs and abstracts for the 16th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2009; Montreal, Canada. Abstract 43LB
- Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myo-cardial infarction and abacavir therapy: No increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr. 2009;51:20–28.
- Benson C, Ribaudo H, Zheng E, et al, and the ACTG A5001/ ALLRT Protocol Team. Infarction or severe cardiovas-cular disease events: results from ACTG A5001. Poster presentation at the 16th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2009; Montreal, Canada. Poster 721
- Cooper D, Bloch M, Humphries A, et al for the STEAL Study Investigators. Simplification with fixed-dose tenofovir/emtricitabine or abacavir/lamivudine in adults with suppressed HIV replication: The STEAL Study, a randomised, open-label, 96 week non-inferiority trial. Poster presentation at the 16th Conference on Retro-viruses and Opportunistic Infections; February 8–11, 2009; Montreal, Canada. Poster 576